Diphtheria-Tetanus-Acellular Pertussis-Polio Adsorbed (DTaP-IPV)  
QUADRACEL®  Supplier: Sanofi Pasteur Limited  
INFANRIX®-IPV  Supplier: GlaxoSmithKline Inc.

INDICATIONS:
• School entry booster given at 4-6 years of age. This is the 5th dose in a routinely immunized child.  
• Used to complete the primary series and booster for children under 7 years of age in whom Hib is not indicated (see Part 4 – Biological Products, Haemophilus b Conjugate Vaccine).  

Not approved for use in those 7 years of age and older.

DOSES AND SCHEDULE:
4-6 years of age: 1 dose given as 0.5 mL IM.  

Primary series completion: See Part 1 – Immunization Schedules for appropriate schedule.

BOOSTER DOSES:  
There are no routine additional doses of these vaccines required outside of the above indications.  

SEROLOGICAL TESTING:  
Serological testing is not recommended before or after immunization.

CONTRAINDICATIONS:  
1. History of anaphylactic reaction to a previous dose of diphtheria or tetanus toxoids or to pertussis or polio vaccines or any component of the product.  
2. History of Guillain-Barré syndrome (GBS) within 8 weeks of receipt of a tetanus toxoid without any other cause being identified.

PRODUCT COMPONENTS:  
QUADRACEL®:  
Potential allergens: neomycin, polymyxin B, bovine serum albumin, polysorbate 80.  
Other components: aluminum phosphate, 2-phenoxyethanol, formaldehyde, glutaraldehyde.  

INFANRIX®-IPV:  
Potential allergens: neomycin, polymyxin.  
Other components: aluminum hydroxide, Medium 199.  

PRECAUTIONS:  
Not applicable.

---

A Not necessary if the 4th dose of DTaP or Tdap-containing vaccine was given after the 4th birthday.  
B Refer to Part 1 – Immunization Schedules for information regarding booster doses using the age appropriate tetanus and diphtheria-containing vaccines.
Diphtheria-Tetanus-Acellular Pertussis-Polio Adsorbed (DTaP-IPV)
QUADRACEL®    Supplier: Sanofi Pasteur Limited
INFANRIX®-IPV    Supplier: GlaxoSmithKline Inc.

SPECIAL CONSIDERATIONS:
• A hypotonic-hyporesponsive episode (HHE) following a prior dose of DTaP-containing vaccine is not a contraindication to future immunization.
• Any dose(s) of oral polio vaccine (OPV) received on or after April 1, 2016 will not be considered as a valid dose within the routine BC immunization schedule. For more information, see Part 4 – Biological Products, Polio Vaccine, Special Considerations.

ADVERSE EVENTS:
Local: redness, swelling, pain.  
Systemic: fever, decreased appetite, vomiting, diarrhea, decreased activity, irritability, drowsiness, increased crying.